Cannabis in multiple sclerosis: Women's health concerns

Journal of Cannabis Therapeutics

Volumn 2, Issue 3-4, 2002, Pages 161-175

  Petro, Denis J ^a  

^a NONE   (United States)

Author keywords

Cannabinoids; Cannabis; Multiple sclerosis; Spasticity; Women's medicine

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BACLOFEN; BARBITURIC ACID DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA1A INTERFERON; CANNABINOID; CANNABIS; CENTRAL NERVOUS SYSTEM AGENTS; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXANABINOL; DIAZEPAM; DRONABINOL; GLATIRAMER; HORMONE; INTERFERON BETA SERINE; METHOTREXATE; MITOXANTRONE; MODAFINIL; MUSCLE RELAXANT AGENT; NABILONE; ORAL CONTRACEPTIVE AGENT; SILDENAFIL; STEROID; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ATTENTION DEFICIT DISORDER; AUTONOMIC DYSFUNCTION; BLADDER DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HUMAN; MALE SEXUAL DYSFUNCTION; MEMORY DISORDER; MENOPAUSE; MULTIPLE SCLEROSIS; NONHUMAN; NYSTAGMUS; PAIN; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SCIENTIFIC LITERATURE; SEX DIFFERENCE; SPASTICITY; SYMPTOMATOLOGY; TREMOR;

EID: 0036458652     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v02n03_12     Document Type: Review

References (57)

1. Achiron, A., S. Miron, V. Lavie, R. Margalit, and A. Biegon. 2000. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol 102(1):26-31.
2. Baker, D., G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, J.W. Huffman, and L. Layward. 2000. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404:84-7.
3. Baker, D., G. Pryce, J.L. Croxford, P. Brown, R.G. Pertwee, A. Makriyannis, A. Khanolkar, L. Layward, F. Fezza, T. Bisogno, and V. Di Marzo. 2001. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15(2):300-2.
4. Benedikt, R.A., P. Cristofaro, J.H. Mendelson, and N.K. Mello. 1986. Effects of acute marijuana smoking in post-menopausal women. Psychopharmacol 90:14-7.
5. Benowitz, N.L., and R.T. Jones. 1977. Effect of delta-9-tetrahydrocannabinol on drug distribution and metabolism: antipyrine, pentobarbital and ethanol. Clin Pharmacol Ther 22(3):259-68.
6. 1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse 41:195-202.
7. Birk, K., and R. Rudick. 1986. Pregnancy and multiple sclerosis. Arch Neurol 43:719-26.
8. Brady, C.M., R. DasGupta, O.J. Wiseman, K.J. Berkley, and C.J. Fowler. 2001. Acute and chronic effects of cannabis-based medicinal extract on refractory lower urinary tract dysfunction in patients with advanced multiple sclerosis-early results. Congress of the IACM Abstracts, p. 9.
9. Branas, P., R. Jordan, A. Fry-Smith, A. Burls, and C. Hyde. 2000. Treatment for fatigue in multiple sclerosis: A rapid and systematic review. Health Technol Assess 4(27):1-61.
10. Brown, D.T. 1998. The therapeutic potential for cannabis and its derivatives. Cannabis: The Genus Cannabis. Amsterdam: Harwood Academic.
11. Cambell, F.A., M.R. Tramer, D. Carroll, D.J.M. Reynolds, R.A. Moore, and H.J. McQuay. 2001. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Brit Med J 323:13-16.
12. Christian, M.S. 2001. Introduction/overview: gender-based differences in pharmacologic and toxicologic responses. Int J Toxicol 20(3):145-8.
13. Clifford, D.B. 1983. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol 13:669-71.
14. Compston, A. 1999. Treatment and management of multiple sclerosis. McAlpine's Multiple Sclerosis. New York: Churchill Livingstone.
15. Compston, A. 2001. Multiple sclerosis and other demyelinating diseases. Brain's Diseases of the Nervous System. New York: Oxford University Press.
16. Consroe, P. 1999. Clinical and experimental reports of marijuana and cannabinoids in spastic disorders. Marijuana and Medicine. Totowa, NJ: Humana Press.
17. Consroe, P., R. Musty, J. Rein, W. Tillery, and R. Pertwee. 1997. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38:44-8.
18. Coyle, P.K. 2000. Women's Issues Multiple Sclerosis: Diagnosis, Medical Management, and Rehabilitation New York: Demos Medical Publishing.
19. Dell'Osso, L.F. 2000. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 54(11):2190-1.
20. Dunn, M., and R. Davis. 1974. The perceived effects of marijuana on spinal cord injured males. Paraplegia 12:175.
21. Fergusson, D.M., L.J. Horwood, and K. Northstone. 2002. Maternal use of cannabis and pregnancy outcome. Brit J Obstet Gyn 109(1):21-7.
22. Fried, P.A., B. Watkinson, and R. Gray. 1999. Growth from birth to early adolescence in offspring prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol 21(5):513-25.
23. Gilson, I., and M. Busalacchi. 1998. Marijuana for intractable hiccups. Lancet 351:267.
24. Gracies, J.M., P. Nance, E. Elovic, J. McGuire, and D.M. Simpson. 1997. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle & Nerve 20 Suppl 6:S92-S120.
25. Greenberg, H.S., S.A.S. Werness, J.E. Pugh, R.O. Andrus, D.J. Anderson, and E.F. Domino. 1994. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther 55:324-8.
26. Grinspoon, L., and J.B. Bakalar. 1997. Common medical uses: multiple sclerosis. Marijuana, the Forbidden Medicine. Rev. and exp. Ed. New Haven: Yale University Press.
27. Guzman, M., C. Sanchez, and I. Galve-Roperh. 2001. Control of the cell survival/death decision by cannabinoids. J Mol Med 78:613-25.
28. Hanigan, W.C., R. Destree, and X.T. Truong. 1985. The effect of Δ-9-THC on human spasticity. Clin Pharmacol Ther 35:198.
29. Iversen, L.L. 2000. The Science of Marijuana. New York: Oxford University Press.
30. Irizarry, M.C. 1997. Multiple sclerosis. Neurologic Disorders in Women. Boston: Butterworth-Heinemann.
31. James, T. 1994. The baby and the bathwater. S Afr Med J 84(6):369.
32. LeResche, L. 2001. Gender, cultural, and environmental aspects of pain. Bonica's Management of Pain 3rd Edition Philadelphia: Lippincott Williams & Wilkins.
33. Lyman, W.D., J.R. Sonett, C.F. Brosnan, R. Elkin, and M.B. Bornstein. 1989. Delta-9 tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23:73-81.
34. Martyn, C.N., L.S. Illis, and J. Thom. 1995. Nabilone in the treatment of multiple sclerosis. Lancet 345:579.
35. Maurer, M., V. Henn, A. Dittrich, and A. Hoffmann. 1990. Delta-9 tetrahydrocannabinol shows antispastic and analgesic effects in a single case, double-blind trial. Eur Arch Psych Clin Neurosci 240(1):1-4.
36. Meinck, H.M., P.W. Schonle, and B. Conrad. 1990. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol 236(2):120-2.
37. Mendelson, J.H., P. Cristofaro, J. Ellingboe, R. Benedikt and N.K. Mello. 1985. Acute effects of marijuana on luteinizing hormone in menopausal women. Pharmacol Biochem Behav 23:765-8.
38. Meng, I.D., B.H. Manning, W.J. Martin, and H.L. Fields. 1998. An analgesia circuit activated by cannabinoids. Nature 395:381-3.
39. Mittleman, M.A., R.A. Lewis, M. Maclure, J.B. Sherwood, and J.E. Muller. 2001. Triggering myocardial infarction by marijuana. Circulation 103(23):2805-9.
40. Olek, M.J., and S.J. Khoury. 2000. Multiple Sclerosis. Women and Health. San Diego: Academic Press.
41. O'Shaughnessy, W.B. 1842. On the preparation of the Indian hemp or ganjah (Cannabis indica): the effects on the animal system in health, and their utility in the treatment of tetanus and other convulsive diseases, Trans Med Phys Soc Bombay 8:421-61.
42. Petro, D.J. 1980. Marijuana as a therapeutic agent for muscle spasm or spasticity. Psychosomatics 21(1):81-5.
43. Petro, D.J. and C. Ellenberger. 1981. Treatment of human spasticity with Δ-9-tetrahydrocannabinol. J Clin Pharmacol 21:413S-416S.
44. Physicians' Desk Reference 56th Edition. 2002. Montvale, NJ: Medical Economics.
45. Pope, H.G. 2002. Cannabis, cognition, and residual confounding. J Amer Med Assoc 287(9):1172-4.
46. Pope, H.G., A.J. Gruber, J.I. Hudson, M.A. Huestis, and D. Yurgelun-Todd. 2001. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 58:909-15.
47. Rammohan, K.W., J.H. Rosenberg, D.J. Lynn, A.M. Blumenfeld, C.P. Pollak, and H.N. Nagaraja. 2002. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72(2):179-83.
48. Reynolds, J.R. 1890. On the therapeutic uses and toxic effects of Cannabis indica. Lancet 1:637-8.
49. Runmarker, B. and O. Anderson. 1995. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118:253-61.
50. Rusk, A. and F. Plum. 1998. Neurologic Health and Disorders. In Textbook of Women's Health Philadelphia: Lippincott-Raven.
51. Schon, F., P.E. Hart, T.L. Hodgson, A.L.M. Pambakian, M. Ruprah, E.M. Williamson, and C. Kennard. 1999. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology 53(9):2209-10.
52. Solowij, N., R.S. Stephens, R.A. Roffman, T. Babor, R. Kadden, M. Miller, K. Christiansen, B. McRee, and J. Vendetti. 2002. Cognitive functioning of long-term heavy cannabis users seeking treatment. J Amer Med Assoc 287(9):1123-31.
53. Somerset, M., R. Campbell, D.J. Sharp and T.J. Peters. 2001. What do people with MS want and expect from health-care services? Health Expectations 4:29-37.
54. Tennes, K., N. Avitable, C. Blackard, C. Boyles, B. Hassoun, L. Holmes and M Kreye. 1985. Marijuana, prenatal and postnatal exposure in the human. In: Pinkert, T.M., ed. Current research on the consequences of maternal drug abuse. NIDA Res Monogr 59:48-60.
55. Ungerleider, J.T., T. Andyrsiak, L. Fairbanks, G.W. Ellison, and L.W. Myers. 1988. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Pharmacological Issues in Alcohol and Substance Abuse 7(1):39-50.
56. Whitaker, J., 1998. Effects of pregnancy and delivery on disease activity in multiple sclerosis. N Engl J Med 339:339-40.
57. Wirguin, I., R. Mechoulam, A. Breuer, E. Schezen, J. Weidenfeld, and T. Brenner. 1994. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28:209-14.